Effects of blocking CD24 and CD47 ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia

Abstract

AbstractMantle‐cell lymphoma (MCL) is a B‐cell non‐Hodgkin Lymphoma (NHL) with a poor prognosis, at high risk of relapse after conventional treatment. MCL‐associated tumour microenvironment (TME) is characterized by M2‐like tumour‐associated macrophages (TAMs), able to interact with cancer cells, providing tumour survival and resistance to immuno‐chemotherapy. Likewise, monocyte‐derived nurse‐like cells (NLCs) present M2‐like profile and provide proliferation signals to chronic lymphocytic leukaemia (CLL), a B‐cell malignancy sharing with MCL some biological and phenotypic features. Antibodies against TAMs targeted CD47, a ‘don't eat me’ signal (DEMs) able to quench phagocytosis by TAMs within TME, with clinical effectiveness when combined with Rituximab in pretreated NHL. Recently, CD24 was found as valid DEMs in solid cancer. Since CD24 is expressed during B‐cell differentiation, we investigated and identified consistent CD24 in MCL, CLL and primary human samples. Phagocytosis increased when M2‐like macrophages were co‐cultured with cancer cells, particularly in the case of paired DEMs blockade (i.e. anti‐CD24 + anti‐CD47) combined with Rituximab. Similarly, unstimulated CLL patients‐derived NLCs provided increased phagocytosis when DEMs blockade occurred. Since high levels of CD24 were associated with worse survival in both MCL and CLL, anti‐CD24‐induced phagocytosis could be considered for future clinical use, particularly in association with other agents such as Rituximab.